Indian Parliamentary Committee Lashes Out At Pricing Watchdog NPPA
This article was originally published in The Pink Sheet Daily
Executive Summary
The committee is concerned about the huge gap between claims raised by the National Pharmaceuticals Pricing Authority for overcharging and the actual amounts recovered, so far less than 10 percent of the total.
You may also be interested in...
Free Market Concept Not Applicable In Pharma Sector, Says India NPPA Chairman A.K. Banerjee: An Interview With PharmAsia News
While the need for price control of drugs continues to be a hot topic for debate, Dr A.K. Banerjee, the man carrying the onus of regulating drug prices in India as the chairman of the National Pharmaceuticals Pricing Authority, presents his viewpoint to PharmAsia News' India bureau on the need for price control in the country.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.